Teva’s skinny label SCOTUS petition is a must-watch for generics
The move is the company’s final resort as it seeks to overturn a $235 million damages decision that has major IP implications for the entire pharmaceutical industry
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.